drugset / Trial / NCT03457337
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib versus gefitinib monotherapy
Timeline
- Start
- 2018-03-28
- Primary completion
- 2020-10-31
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |
Indications
No indication recorded.